-
EP3302479
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3302479
| EP3302479 - TUMOR BIOMARKERS AND USE THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 22.09.2023 Database last updated on 19.10.2024 | |
| Former | Examination is in progress Status updated on 04.07.2020 | ||
| Former | Request for examination was made Status updated on 09.03.2018 | ||
| Former | The international publication has been made Status updated on 02.12.2016 | Most recent event Tooltip | 22.09.2023 | Application deemed to be withdrawn | published on 25.10.2023 [2023/43] | Applicant(s) | For all designated states Curegenix Corporation 332 Beach Road Burlingame, California 94010 / US | [2018/15] | Inventor(s) | 01 /
QIN, Xiaoli c/o 332 Beach Road Burlingame, California 94010 / US | 02 /
AN, Songzhu c/o 332 Beach Road Burlingame, California 94010 / US | 03 /
HUANG, Tao c/o 332 Beach Road Burlingame, California 94010 / US | [2018/15] | Representative(s) | Murgitroyd & Company 165-169 Scotland Street Glasgow G5 8PL / GB | [N/P] |
| Former [2018/15] | Green, Mark Charles Urquhart-Dykes & Lord LLP Euston House 24 Eversholt Street London NW1 1AD / GB | Application number, filing date | 16800691.4 | 26.05.2016 | [2018/15] | WO2016US34245 | Priority number, date | US201562166305P | 26.05.2015 Original published format: US 201562166305 P | [2018/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016191525 | Date: | 01.12.2016 | Language: | EN | [2016/48] | Type: | A1 Application with search report | No.: | EP3302479 | Date: | 11.04.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.12.2016 takes the place of the publication of the European patent application. | [2018/15] | Search report(s) | International search report - published on: | US | 01.12.2016 | (Supplementary) European search report - dispatched on: | EP | 11.12.2018 | Classification | IPC: | A61K31/4985, A61K31/4725, A61K31/444, A61P35/00 | [2019/02] | CPC: |
A61K31/444 (EP,KR,US);
C12Q1/6886 (US);
A61K31/4725 (EP,KR,US);
A61K31/4985 (EP,KR,US);
A61P35/00 (EP,KR,US);
G01N33/57484 (EP,KR,US);
|
| Former IPC [2018/15] | A61K31/4985, A61K31/4725, A61K31/444 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/15] | Title | German: | TUMORBIOMARKER UND VERWENDUNG DAVON | [2018/15] | English: | TUMOR BIOMARKERS AND USE THEREOF | [2018/15] | French: | BIOMARQUEURS TUMORAUX ET LEUR UTILISATION | [2018/15] | Entry into regional phase | 28.11.2017 | National basic fee paid | 28.11.2017 | Search fee paid | 28.11.2017 | Designation fee(s) paid | 28.11.2017 | Examination fee paid | Examination procedure | 28.11.2017 | Examination requested [2018/15] | 28.11.2017 | Date on which the examining division has become responsible | 05.06.2019 | Amendment by applicant (claims and/or description) | 08.07.2020 | Despatch of a communication from the examining division (Time limit: M06) | 13.01.2021 | Reply to a communication from the examining division | 19.01.2023 | Despatch of a communication from the examining division (Time limit: M04) | 31.05.2023 | Application deemed to be withdrawn, date of legal effect [2023/43] | 21.06.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2023/43] | Fees paid | Renewal fee | 29.05.2018 | Renewal fee patent year 03 | 28.05.2019 | Renewal fee patent year 04 | 27.05.2020 | Renewal fee patent year 05 | 27.05.2021 | Renewal fee patent year 06 | 27.05.2022 | Renewal fee patent year 07 | 30.05.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2013130364 (NOVARTIS AG [CH], et al) [Y] 1-14 * claims 26-30 *; | [Y] - J. LIU ET AL, "Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20131125), vol. 110, no. 50, doi:10.1073/pnas.1314239110, ISSN 0027-8424, pages 20224 - 20229, XP055121007 [Y] 1-14 * page 20225 - page 20226 * DOI: http://dx.doi.org/10.1073/pnas.1314239110 | [Y] - SOMASEKAR SESHAGIRI ET AL, "Recurrent R-spondin fusions in colon cancer", NATURE, (20120101), vol. 488, no. 7413, doi:10.1038/nature11282, ISSN 0028-0836, pages 660 - 664, XP055060432 [Y] 1-14 * page 662 - column 663; figures 3,4 * DOI: http://dx.doi.org/10.1038/nature11282 | [Y] - Gabriela Cardona, "Abstract 2408: Identification of R-Spondin fusions in various types of human cancer | Cancer Research", Cancer Research, doi:10.1158/1538-7445.AM2014-2408, (20141010), URL: http://cancerres.aacrjournals.org/content/74/19_Supplement/2408, (20170928), XP055411087 [Y] 1-14 * page 2 * DOI: http://dx.doi.org/10.1158/1538-7445.AM2014-2408 | International search | [Y]US2013209473 (DE SAUVAGE FREDERIC J [US], et al) [Y] 3, 4/3, 25, 26/25 * ; abstract; paragraphs [0003], [0008], [0016], [0125], [0345] *; | [XY]WO2014165232 (CUREGENIX INC [CN], et al) [X] 1-2, 4/1-2, 5, 23-24, 26/23-24, 27 * ; abstract; paragraphs [0015], [0016], [0026], [0028], [0034], [0047], [0131], [0163], [0166]; figure 3; SEQ ID NO: 17 * [Y] 3, 4/3, 25, 26/25; | [A] - AN, SM et al., "Stem Cell Signaling as a Target for Novel Drug Discovery: Recent Progress in the WNT and Hedgehog Pathways.", Acta Pharmacologica Sinica., (20130527), vol. 34, no. 6, pages 777 - 783, XP055331885 [A] 1-3, 4/1-3, 5, 23-25, 26/23-25, 27 * ; entire document * DOI: http://dx.doi.org/10.1038/aps.2013.64 |